Janux Therapeutics (NASDAQ:JANX) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of Janux Therapeutics (NASDAQ:JANX) from a hold rating to a sell rating in a research note issued to investors on Saturday morning.

Other equities analysts have also issued research reports about the stock. Barclays cut their price objective on shares of Janux Therapeutics from $48.00 to $29.00 and set an “overweight” rating on the stock in a report on Wednesday, December 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Janux Therapeutics in a research note on Thursday, January 22nd. HC Wainwright dropped their target price on Janux Therapeutics from $70.00 to $45.00 and set a “buy” rating on the stock in a research report on Tuesday, December 2nd. Wedbush reiterated an “outperform” rating and issued a $45.00 price target (down from $76.00) on shares of Janux Therapeutics in a research note on Tuesday, December 2nd. Finally, Bank of America lowered their price objective on Janux Therapeutics from $58.00 to $49.00 and set a “buy” rating for the company in a research note on Tuesday, December 2nd. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $56.91.

Janux Therapeutics Stock Performance

Janux Therapeutics stock opened at $13.18 on Friday. The firm has a market capitalization of $801.74 million, a PE ratio of -7.20 and a beta of 2.88. Janux Therapeutics has a one year low of $12.12 and a one year high of $35.34. The stock’s 50 day moving average price is $13.68 and its 200 day moving average price is $19.29.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.14. The firm had revenue of $7.88 million during the quarter, compared to analyst estimates of $0.08 million. On average, analysts forecast that Janux Therapeutics will post -1.38 earnings per share for the current fiscal year.

Insider Activity at Janux Therapeutics

In other news, insider Zachariah Mciver sold 2,714 shares of the business’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $13.73, for a total value of $37,263.22. Following the completion of the sale, the insider owned 23,286 shares of the company’s stock, valued at approximately $319,716.78. The trade was a 10.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO David Alan Campbell sold 8,072 shares of the business’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $13.73, for a total transaction of $110,828.56. Following the completion of the sale, the chief executive officer directly owned 284,982 shares of the company’s stock, valued at $3,912,802.86. The trade was a 2.75% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 19,033 shares of company stock worth $261,323 over the last 90 days. Company insiders own 8.10% of the company’s stock.

Institutional Trading of Janux Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Nano Cap New Millennium Growth Fund L P bought a new position in Janux Therapeutics during the 4th quarter worth approximately $34,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Janux Therapeutics in the 4th quarter valued at approximately $51,000. Osaic Holdings Inc. raised its position in shares of Janux Therapeutics by 704.6% during the 2nd quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock valued at $80,000 after acquiring an additional 3,037 shares in the last quarter. Virtus Investment Advisers LLC lifted its stake in Janux Therapeutics by 37.9% during the second quarter. Virtus Investment Advisers LLC now owns 3,679 shares of the company’s stock worth $85,000 after purchasing an additional 1,011 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in Janux Therapeutics by 175.5% during the second quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock worth $91,000 after purchasing an additional 2,502 shares during the last quarter. 75.39% of the stock is owned by institutional investors.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.